CC BY
23
ГЕМОБЛАСТОЗЫ: ДИАГНОСТИКА, ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯ
29
52. Katodritou E., Terpos E., Zervas K. et al. Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response
to erythropoietin in anemic patients with myeloma and lymphoma. Ann Hematol 2007;86(5):369-76.
53. Romanenko N.A., Golovtshenko R.A., Kostroma I.I., Abdulkadyrov K.M. Study of efficacy recombinant human erythropoietin in multiple myeloma patients with anemia. Haematologica 2012;97(Suppl. 1):622.
54. Richardson P., Schlag R., Khuageva N. et al. Characterization of haematological parameters with bortezomib—melphalan— prednisone versus melphalan—prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use
of erythropoiesis-stimulating agents: analysis of the VISTA trial. Br J Haematol 2011; 153(2):212-21.
55. Santini V. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes. Oncologist 2011;16(Suppl. 3): 35-42.
56. Villegas A., Arrizabalaga B., Fernandez-Lago C. et al. Darbepoetin alfa for anemia in patients with low
or intermediate-1 risk myelodysplastic
syndromes and positive predictive factors of response. Curr Med Res Opin 2011; 27(5):951-60.
57. Park S., Kelaidi C., Sapena R. et al.
Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients. Leuk Res 2010;34(11):1430-6.
58. Cervantes F., Alvarez-Larran A., Hernandez-Boluda J.C. et al. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in
20 patients and review of the literature.
Br J Haematol 2004;127(4):399-403.
59. Nagel S., Kellner O., Engel-Riedel W. et al. Addition of darbepoetin alfa to dose-dense chemotherapy: results from
a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide. Clin Lung Cancer 2011; 12(1):62-9.
60. Eisterer W., Hussl C., Erb H. et al. RETRA: evaluating the transfusion rate with darbepoetin alfa 500 ^g every 3 weeks in anaemic cancer patients receiving chemotherapy. Curr Med Res Opin 2011; 27(2):355-63.
61. Steensma D.P., Sloan J.A., Dakhil S.R. et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no
iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 2011;29(1):97-105.
62. Ludwig H., Crawford J., Osterborg A. et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin
alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009;27(17):2838-47.
63. Vansteenkiste J., Glaspy J., Henry D. et al. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: Study-level and patient-level meta-analyses. Lung Cancer 2012;76(3):478-85.
64. Bastit L., Vandebroek A., Altintas S. et al. Randomized, multicenter, controlled trial comparing the efficacy and safety
of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26(10):1611-8.
65. Katodritou E., Speletas M., Zervas K. et al. Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma. Lab Hematol 2006;12(1):47-54.
3 ’201 2
